STAT+: Bernie Sanders targets ‘outrageously high price’ of Ozempic
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Here in Chicago, residents are reeling over the removal of the famed rat hole, a rat-shaped indentation on a piece of sidewalk that drew crowds, fans, and even a proposal and a marriage.
The need-to-know this morning
- AstraZeneca reported first-quarter sales and profits that topped analyst estimates, buoyed by its blockbuster cancer drugs.
- It’s a busy day for pharma earnings: Merck, Sanofi, Daiichi Sankyo, Astellas, and Bristol Myers Squibb.
- Regeneron Pharmaceuticals and Mammoth Biosciences are partnering to develop new CRISPR-based gene therapies.
A hospital takes a gene therapy’s approval into its own hands
What happens if, as an academic, you develop a promising gene therapy, but no company is willing to take it to market? Well, one option is — you do it yourself.
Continue to STAT+ to read the full story…
Read Original Article: STAT+: Bernie Sanders targets ‘outrageously high price’ of Ozempic »
